作者
Frank A Sinicrope, Qian Shi, Thomas C Smyrk, Stephen N Thibodeau, Rodrigo Dienstmann, Justin Guinney, Brian M Bot, Sabine Tejpar, Mauro Delorenzi, Richard M Goldberg, Michelle Mahoney, Daniel J Sargent, Steven R Alberts
发表日期
2015/1/1
期刊
Gastroenterology
卷号
148
期号
1
页码范围
88-99
出版商
WB Saunders
简介
Background & Aims
Categorization of colon cancers into distinct subtypes using a combination of pathway-based biomarkers could provide insight into stage-independent variability in outcomes.
Methods
We used a polymerase chain reaction–based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147). Tumors deficient or proficient in DNA mismatch repair (MMR) were identified based on detection of MLH1, MSH2, and MSH6 proteins and methylation of the MLH1 promoter. Findings were validated using tumor samples from a separate set of patients with stage III cancer (n = 783). Association with 5-year disease-free survival was evaluated using Cox proportional hazards models.
Results
Tumors were categorized into 5 subtypes based on MMR status and detection of BRAF or …
学术搜索中的文章
FA Sinicrope, Q Shi, TC Smyrk, SN Thibodeau… - Gastroenterology, 2015